


FIGURE 1

BEST AVAILABLE COPY



\* Part of biomarker discovery set. <sup>†</sup> In Panels A, C, E, and G, epithelial ovarian cancer included both invasive and borderline tumors.

FIGURE 2




FIGURE 3





FIGURE 4



Transthyretin assays  
Fig. 6




Fig. 7

## Scatter plots from patient samples



\*  $p < .01$ ; \*\*  $p < .001$

Fig. 8  
Acid hydrolysis demonstrates cysteininylation





9/12




Fig. 9




Fig. 10




Fig. 11

10/12




Fig. 12




Fig. 13




Fig. 14

# Apo A1 peaks on IMAC30 Cu array (PBSIIC)

Intergen serum after enrichment on IDA-Ni peaks





Fig. 15

# Apo A1 peaks on IMAC30 Cu array (PCS4000)

## SAIC protocol – Intergen serum direct binding without enrichment

WO 2005/098447

12/12





Fig 1b

PCT/US2005/010783

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record.**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

## **IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**